Thermo Fisher mycoplasma detection tech accepted for cell therapies

By Flora Southey contact

- Last updated on GMT

GettyImages/man_at_mouse
GettyImages/man_at_mouse
Thermo Fisher Scientific’s mycoplasma detection kit has been accepted by regulators for quality assurance, quality control and lot release.

The Applied Biosystems MycoSEQ Mycoplasma Detection Kit provides manufacturers of cell-culture-based therapeutics a faster method for detecting contamination, said the vendor.

The MycoSEQ assay can detect more than 90 mycoplasma species in less than five hours, offering drugmakers an alternative to “costly, time-consuming culture-based tests often done by externally contract labs, which can take up to 28 days,” ​the firm said.

The assay and method can be used for lot release by drugmakers of biotherapeutics, cell and gene therapies, vaccines, and other cell-culture-based medicines.

Head of pharma analytics Michael Brewer told us the technology was recently granted patents that cover its multiplexed PCR (polymerase chain reaction) primer approach and discriminatory positive/extraction control.

“These innovations to real-time PCR technology, which are unique to us, enable this rapid test for mycoplasma to meet the increasingly rigorous requirements of both regulatory authorities and manufacturers.”

Multiple pharmaceutical companies are using the assay, we were told.

“Several global manufacturers, including Vericel, across multiple therapeutic modalities have successfully validated the assay and achieved regulatory approval for lot release,” ​said Brewer. 

The technology is available to manufacturers worldwide.

Related news

Related products

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars